The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update

References

• Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P. (2008). Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 158:273–80.
   PubMed Web of Science ®Google Scholar
• Abu-Alfa AK. (2011). Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv Chronic Kidney Dis 18:188–98.
   PubMedGoogle Scholar
• ACR. (2013). Manual on Contrast Media. Version 9. Available at: http://www.acr.org/quality-safety/resources/∼/media/37D84428BF1D4E1B9A3A2918DA9E27A3.pdf/. Accessed on 8 September 2014.
   Google Scholar
• Adding LC, Bannenberg GL, Gustafsson LE. (2001). Basic experimental studies and clinical aspects of gadolinium salts and chelates. Cardiovasc Drug Rev 19:41–56.
   PubMed Web of Science ®Google Scholar
• Akimoto T, Kimura T, Watanabe Y, Ishikawa N, Iwazu Y, Saito O, et al. (2013). The impact of nephrectomy and renal transplantation on serum levels of soluble Klotho protein. Transplant Proc 45:134–6.
   PubMed Web of Science ®Google Scholar
• Allen JA, Peterson A, Sufit R, Hinchcliff ME, Mahoney JM, Wood TA, et al. (2011). Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. Arthritis Rheum 63:3633–9.
   PubMedGoogle Scholar
• Anonymous. (2014). Long Term Retention of Gadolinium in Bone. ClinicalTrials.gov identifier: NCT01853163. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01853163?term = BONE+ gadolinium&rank = 1. (Accessed on 13 August 2014)
   Google Scholar
• Barker-Griffith A, Goldberg J, Abraham JL. (2011). Ocular pathologic features and gadolinium deposition in nephrogenic systemic fibrosis. Arch Ophthalmol 129:661–3.
   PubMedGoogle Scholar
• Barton Pai A, Conner TA, McQuade CR. (2009). Therapeutic use of the phosphate binder lanthanum carbonate. Expert Opin Drug Metab Toxicol 5:71–81.
   PubMed Web of Science ®Google Scholar
• Behets GJ, Verberckmoes SC, Oste L, Bervoets AR, Salomé M, Cox AG, et al. (2005). Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 67:1830–6.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Qureshi ZP, Sartor AO, Norris LB, Murday A, Xirasagar S, Thomsen HS. (2012). Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clin Kidney J 5:82–8.
   PubMedGoogle Scholar
• Bernstein EJ, Isakova T, Sullivan ME, Chibnik LB, Wolf M, Kay J. (2014). Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control-study. Rheumatology (Oxford) 53:1613–7.
   PubMedGoogle Scholar
• Bhagavathula N, Dame MK, DaSilva M, Jenkins W, Aslam MN, Perone P, Varani J. (2010). Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Invest Radiol 45:769–77.
   PubMedGoogle Scholar
• Bhagavathula N, DaSilva M, Aslam MN, Dame MK, Warner RL, Xu Y, Varani J, et al. (2009). Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. Invest Radiol 44:433–9.
   PubMedGoogle Scholar
• Bleavins K, Perone P, Naik M, Rehman M, Aslam MN, Dame MK, et al. (2012). Stimulation of fibroblast proliferation by insoluble gadolinium salts. Biol Trace Elem Res 145:257–67.
   PubMed Web of Science ®Google Scholar
• Boin F, Hummers LK. (2008). Scleroderma-like fibrosing disorders. Rheum Dis Clin North Am 34:199–220.
   PubMed Web of Science ®Google Scholar
• Bonnemain B, Meyer D. (1985). Present Aspects of MRI Contrast Agents – Early Experience with DOTA Gadolinium. MR’85. Internationales Kernspintomographie Symposium; Garmisch Partenkirschen. 81–88. (Abstract)
   Google Scholar
• Boyd AS, Zic JA, Abraham JL. (2007). Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56:27–30.
   PubMed Web of Science ®Google Scholar
• Brambilla S, Valaperta S, Graziani G, Montanelli A. (2008). Gadolinium and lanthanum: an iatrogenic transmetallation? Clin Biochem 41:1029–33.
   PubMedGoogle Scholar
• Bucala R. (2008). Circulating fibrocytes: cellular basis for NSF. J Am Coll Radiol 5:36–9.
   PubMedGoogle Scholar
• Bucala R. (2012). Review Series - Inflammation & Fibrosis. Fibrocytes and fibrosis. Q J Med 105:505–8.
   Google Scholar
• Cabella C, Crich SG, Corpillo D, Barge A, Ghirelli C, Bruno E, et al. (2006)Cellular labeling with Gd(III) chelates: only high thermodynamic stabilities prevent the cells acting as ‘sponges’ of Gd3+ ions. Contrast Media Mol Imaging 1:23–9.
   PubMed Web of Science ®Google Scholar
• Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. (1999). Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 99:2293–52.
   PubMed Web of Science ®Google Scholar
• Chachuat A, Molinier P, Bonnemain B, Chambon C, Gayet JL. (1992). Pharmacokinetics and tolerance of Gd-DOTA (Dotarem) in healthy volunteers and in patients with chronic renal failure. Eur Radiol 2: 326–9.
   Google Scholar
• Chandran S, Petersen J, Jacobs C, Fiorentino D, Doeden K, Lafayette RA. (2009). Imatinib in the treatment of nephrogenic systemic fibrosis. Am J Kidney Dis 53:129–32.
   PubMedGoogle Scholar
• Christensen KN, Lee CU, Hanley MM, Leung N, Moyer TP, Pittelkow MR. (2011). Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 64:91–6.
   PubMed Web of Science ®Google Scholar
• Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. (2000). Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356:1000–1001.
   PubMed Web of Science ®Google Scholar
• Cowper SE, Rabach M, Girardi M. (2008). Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 66: 191–99.
   PubMed Web of Science ®Google Scholar
• Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, Ellen Campbell M, Hauschka PV, Hannigan RE. (2009). Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics 1:479–88.
   PubMed Web of Science ®Google Scholar
• DaSilva M, O’Brien Deming M, Fligiel SE, Dame MK, Johnson KJ, Swartz RD, Varani J. (2010). Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Invest Radiol 45:733–9.
   PubMedGoogle Scholar
• De Broe ME. (2008). Can the risk of gadolinium be extrapolated to lanthanum? Semin Dial 21:142–4.
   PubMedGoogle Scholar
• Del Galdo F, Wermuth PJ, Addya S, Fortina P, Jimenez SA. (2010). NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. Ann Rheum Dis 69:2024–33.
   PubMedGoogle Scholar
• Deng A, Martin DB, Spillane A, Chwalek J, St Surin-Lord S, Brooks S, et al. (2010). Nephrogenic systemic fibrosis with a spectrum of clinical and histopathological presentation: a disorder of aberrant dermal remodeling. J Cutan Pathol 37:204–10.
   PubMedGoogle Scholar
• D’Haese PC, Couttenye MM, Lamberts LV, Elseviers MM, Goodman WG, Schrooten I, et al. (1999). Aluminum, iron, lead, cadmium, copper, zinc, chromium, magnesium, strontium, and calcium content in bone of end-stage renal failure patients. Clin Chem 45:1548–56.
   PubMed Web of Science ®Google Scholar
• Di Gregorio E, Gianolio E, Stefania R, Barutello G, Digilio G, Aime S. (2013). On the fate of MRI Gd-based contrast agents in cells. Evidence for extensive degradation of linear complexes upon endosomal internalization. Anal Chem 85:5627–31.
   Google Scholar
• Do C, Barnes JL, Tan C, Wagner B. (2014). Type of MRI contrast, tissue gadolinium, and fibrosis. Am J Physiol Renal Physiol 307:F844–55.
   Google Scholar
• Doi S, Zou Y, Togao O, Pastor JV, John GB, Wang L, et al. (2011). Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 286:8655–65.
   PubMed Web of Science ®Google Scholar
• Drouven BJ, Evans CH. (1986). Collagen fibrillogenesis in the presence of lanthanides. J Biol Chem 261:11792–7.
   PubMedGoogle Scholar
• Edward M, Quinn JA, Mukherjee S, Jensen MB, Jardine AG, Mark PB, Burden AD. (2008). Gadodiamide contrast agent ‘activates’ fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 214: 584–93. Erratum in: J Pathol 214:593.
   PubMedGoogle Scholar
• Edward M, Quinn JA, Burden AD, Newton BB, Jardine AG. (2010). Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology 256:735–43.
   PubMed Web of Science ®Google Scholar
• Elmholdt TR, Pedersen M, Jørgensen B, Ramsing M, Olesen AB. (2011). Positive effect of low-dose imatinib mesylate in a patient with nephrogenic systemic fibrosis. Acta Derm Venereol 91:478–9.
   PubMedGoogle Scholar
• Emmez H, Kardes O, Dogulu F, Kurt G, Memis L, Baykaner MK.Role of antifibrotic cytokine interferon-gamma in the prevention of postlaminectomy peridural fibrosis in rats. (2008). Neurosurgery 62:1351–7.
   PubMed Web of Science ®Google Scholar
• Errante Y, Cirimele V, Mallio CA, Di Lazzaro V, Zobel BB, Quattrocchi CC. (2014). Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 49:685–90.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency. (2010). Assessment Report for Gadolinium-Containing Contrast Agents. Procedure No. EMEA/H/A-31/1097. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/gadolinium_31/WC500099538.pdf. Accessed on 12 August 2014.
   Google Scholar
• Evans CH. Biochemistry of the Lanthanides. Biochemistry of the Elements. (1990). New York: Plenum Press, pp. 85–315.
   Google Scholar
• Filopanti M, Corbetta S, Barbieri AM, Spada A. (2013)Pharmacology of the calcium sensing receptor. Clin Cases Miner Bone Metab 10:162–5.
   PubMedGoogle Scholar
• Food and Drug Administration. US Department of Health and Human Services. Center for Drug Evaluation and Research. Guidance for industry. (2005). Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf. Accessed on 13 August 2014.
   Google Scholar
• Frenzel T, Lengsfeld P, Schirmer H, Hütter J, Weinmann HJ. (2008). Stability of gadolinium-based contrast agents in human serum at 37°C. Invest Radiol 43:817–28.
   PubMed Web of Science ®Google Scholar
• Fretellier N, Idée JM, Guerret S, Hollenbeck C, Hartmann D, González W, et al. (2011a). Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol 46:85–93.
   PubMedGoogle Scholar
• Fretellier N, Idée JM, Dencausse A, Karroum O, Guerret S, Poveda N, et al. (2011b). Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol 46: 292–300.
   PubMed Web of Science ®Google Scholar
• Fretellier N, Idée J, Bruneval P, Guerret S, Daubiné F, Jestin G, et al. (2012). Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide. Br J Pharmacol 165:1151–62.
   PubMed Web of Science ®Google Scholar
• Fretellier N, Bouzian N, Parmentier N, Bruneval P, Jestin G, Factor C, et al. (2013). Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure. Toxicol Sci 131:259–70. Erratum in: Toxicol Sci 132:252.
   PubMedGoogle Scholar
• Friman C, Storgårds E, Juvani M, Kock B. (1977). The glycosaminoglycans (mucopolysaccharides) in plasma in patients with renal insufficiency. Clin Nephrol 8:435–9.
   PubMedGoogle Scholar
• George SJ, Webb SM, Abraham JL, Cramer SP. (2010). Synchrotron X-ray analyses demonstrate phosphate-bound gadolinium in skin in nephrogenic systemic fibrosis. Br J Dermatol 163:1077–81.
   PubMedGoogle Scholar
• Girardi M, Kay J, Elston DM, Leboit PE, Abu-Alfa A, Cowper SE. (2011). Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 65:1095–106.
   PubMedGoogle Scholar
• Goddard DS, Magee CC, Lazar AJ, Miller DM. (2007). Nephrogenic fibrosing dermopathy with recurrence after allograft failure. J Am Acad Dermatol 56:S109–S11.
   Google Scholar
• Goveia M, Chan BP, Patel PR. (2007). Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis. J Am Acad Dermatol 57:725–7.
   PubMedGoogle Scholar
• Grant D, Johnsen H, Juelsrud A, Løvhaug D. (2009). Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis. Acta Radiol 50:156–169.
   PubMed Web of Science ®Google Scholar
• Grobner T. (2006). Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104–8. Erratum in: Nephrol Dial Transplant 21:1745.
   PubMed Web of Science ®Google Scholar
• Groves RW, Simpson KJ, Koblar S, Pitzalis C, Hay RJ. (1992). Tryptophan induced eosinophilia-myalgia syndrome: clinical and microscopic findings. J R Soc Med 85:111–2.
   PubMedGoogle Scholar
• Harrison A, Walker CA, Pereira KA, Parker D, Royle L, Pulukkody K, Norman TJ. (1993). Hepato-biliary and renal excretion in mice of charged and neutral gadolinium complexes of cyclic tetra-aza-phosphinic and carboxylic acids. Magn Reson Imaging 11:761–70.
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Matsumoto K, Gon Y, Nakayama T, Takeshita I, Horie T. (1999). Hyperosmolarity-induced interleukin-8 expression in human bronchial epithelial cells through p38 mitogen-activated protein kinase. Am J Respir Crit Care Med 159:634–40.
   PubMed Web of Science ®Google Scholar
• Haylor J, Dencausse A, Vickers M, Nutter F, Jestin G, Slater D, et al. (2010). Nephrogenic gadolinium biodistribution and skin cellularity following a single injection of Omniscan in the rat. Invest Radiol 45:507–12.
   PubMedGoogle Scholar
• Haylor J, Schroeder J, Wagner B, Nutter F, Jestin G, Idée JM, Morcos S. (2012). Skin gadolinium following use of MR contrast agents in a rat model of nephrogenic systemic fibrosis. Radiology 263:107–16.
   PubMed Web of Science ®Google Scholar
• High WA, Ayers RA, Chandler J, Zito G, Cowper SE. (2007). Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:21–6.
   PubMed Web of Science ®Google Scholar
• High WA, Ranville JF, Brown M, Punshon T, Lanzirotti A, Jackson BP. (2010). Gadolinium deposition in nephrogenic systemic fibrosis: an examination of tissue using synchrotron x-ray fluorescence spectroscopy. J Am Acad Dermatol 62:38–44.
   PubMedGoogle Scholar
• Hill AB. (1965). The environment and disease: association or causation? Proc R Soc Med 58:295–300.
   PubMed Web of Science ®Google Scholar
• Hirano S, Suzuki KT. (1996). Exposure, metabolism, and toxicity of rare earths and related compounds. Environ Health Perspect 104:85–95.
   PubMed Web of Science ®Google Scholar
• Hope TA, High WA, Leboit PE, Chaopathomkul B, Rogut VS, Herfkens RJ, Brasch RC. (2009). Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. Radiology 253:390–8.
   PubMedGoogle Scholar
• Hope TA, LeBoit P, High WA, Fu Y, Brasch RC. (2013). Evaluation of imatinib mesylate as a possible treatment for nephrogenic systemic fibrosis in a rat model. Magn Reson Imaging 31:139–44.
   PubMedGoogle Scholar
• Hutchinson AJ, Barnett ME, Krause R, Kwan JTC, Siami GA, on behalf of the SPD405–309 Lanthanum Study group. (2008). Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract 110:c15–c23.
   Google Scholar
• Idée JM, Port M, Robic C, Medina C, Sabatou M, Corot C. (2009a). Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging 30:1249–58.
   PubMed Web of Science ®Google Scholar
• Idée JM, Port M, Dencausse A, Lancelot E, Corot C. (2009b). Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 47:855–69
   PubMedGoogle Scholar
• Jenkins W, Perone P, Walker K, Bhagavathula N, Aslam MN, DaSilva M, et al. (2011). Fibroblast response to lanthanoid metal ion stimulation: potential contribution to fibrotic tissue injury. Biol Trace Elem Res 144:621–35.
   PubMed Web of Science ®Google Scholar
• Kanapilly GM. (1980). In vitro precipitation behavior of trivalent lanthanides. Health Phys 39:343–6.
   PubMedGoogle Scholar
• Kay J, High WA. (2008). Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 58:2543–8.
   PubMed Web of Science ®Google Scholar
• Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. (2014). High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270:834–41.
   PubMed Web of Science ®Google Scholar
• Kelly B, Petitt M, Sanchez R. (2008). Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of renin-angiotensin system involvement. J Am Acad Dermatol 58:1025–30.
   PubMedGoogle Scholar
• Kurtkoti J, Snow T, Hiremagalur B. (2008). Gadolinium and nephrogenic systemic fibrosis: association or causation. Nephrology (Carlton) 13:235–41.
   PubMed Web of Science ®Google Scholar
• Langer RD, Lorke DE, Neidl van Gorkom KF, Petroianu G, Azimullah S, Nurulain SM, et al. (2012). In an animal model nephrogenic systemic fibrosis cannot be induced by intraperitoneal injection of high-dose gadolinium based contrast agents. Eur J Radiol 81:2562–7.
   PubMedGoogle Scholar
• Laurent S, Vander Elst L, Copoix F, Muller RN. (2001). Stability of MRI paramagnetic contrast media: a proton relaxometric protocol for transmetallation assessment. Invest Radiol 36:115–22.
   PubMed Web of Science ®Google Scholar
• Laurent S, Elst LV, Muller RN. (2006). Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 1:128–37.
   PubMed Web of Science ®Google Scholar
• Laurent S, Vander Elst L, Henoumont C, Muller RN. (2010). How to measure the transmetallation of a gadolinium complex. Contrast Media Mol Imaging 5:305–8.
   PubMedGoogle Scholar
• Li JX, Liu JC, Wang K, Yang XG. (2010). Gadolinium-containing bioparticles as an active entity to promote cell cycle progression in mouse embryo fibroblast NIH3T3 cells. J Biol Inorg Chem 15: 547–57.
   PubMed Web of Science ®Google Scholar
• Li JX, Fu LJ, Yang XG, Wang K. (2012). Integrin-mediated signaling contributes to gadolinium-containing-particle-promoted cell survival and G to S phase cell cycle transition by enhancing focal adhesion formation. J Biol Inorg Chem 17:375–85.
   PubMedGoogle Scholar
• MacNeil S, Bains S, Johnson C, Idée JM, Factor C, Jestin G, et al. (2011). Gadolinium contrast agent associated stimulation of human fibroblast collagen production. Invest Radiol 46:711–7.
   PubMedGoogle Scholar
• Manjunath V, Perazella MA. (2011). Imaging patients with kidney disease in the era of NSF: can it be done safely? Clin Nephrol 75:279–85.
   PubMedGoogle Scholar
• Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS. (2006). Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359–62.
   PubMed Web of Science ®Google Scholar
• Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. (2007). Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 22:3174–8.
   PubMed Web of Science ®Google Scholar
• Martin DR, Semelka RC, Chapman A, Peters H, Finn PJ, Kalb B, Thomsen H. (2009). Nephrogenic systemic fibrosis versus contrast-induced nephropathy: risks and benefits of contrast-enhanced MR and CT in renally impaired patients. J Magn Reson Imaging 30: 1350–6.
   PubMedGoogle Scholar
• Messeguer A. (2011). Potential implication of aniline derivatives in the toxic oil syndrome (TOS). Chem Biol Interact 192:136–41.
   PubMed Web of Science ®Google Scholar
• Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. (2008). The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 40: 362–82.
   PubMed Web of Science ®Google Scholar
• Morcos SK. (2007). Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 80:73–6.
   PubMedGoogle Scholar
• Newton BB, Jimenez SA. (2009). Mechanism of NSF: New evidence challenging the prevailing theory. J Magn Reson Imaging 30: 1277–83.
   PubMedGoogle Scholar
• Palasz A, Czekaj P. (2000)Toxicological and cytophysiological aspects of lanthanides action. Acta Biochim Pol 47:1107–14.
   PubMed Web of Science ®Google Scholar
• Panesar M, Banerjee P, Barone GW. (2008). Clinical Improvement of nephrogenic systemic fibrosis after kidney transplantation. Clin Transplant 23:803–8.
   Google Scholar
• Perazella MA, Reilly RF. (2010). Imaging patients with kidney disease: how do we approach contrast-related toxicity? Am J Med Sci 341: 215–21.
   Google Scholar
• Perone PA, Weber SL, DaSilva M, Paruchuri T, Bhagavathula N, Aslam MN, et al. (2010). Collagenolytic activity is suppressed in organ-cultured human skin exposed to a gadolinium-based MRI contrast agent. Invest Radiol 45:42–8.
   PubMedGoogle Scholar
• Pietsch H, Lengsfeld P, Steger-Hartmann T, Löwe A, Frenzel T, Hütter J, Sieber MA. (2009a). Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol 44:226–33.
   PubMedGoogle Scholar
• Pietsch H, Pering C, Lengsfeld P, Walter J, Steger-Hartmann T, Golfier S, et al. (2009b). Evaluating the role of zinc in the occurrence of fibrosis of the skin: a preclinical study. J Magn Reson Imaging 30:374–83.
   PubMedGoogle Scholar
• Pietsch H, Raschke M, Ellinger-Ziegelbauer H, Jost G, Walter J, Frenzel T, et al. (2011a). The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats. Invest Radiol 46:48–56.
   PubMedGoogle Scholar
• Pietsch H, Jost G, Frenzel T, Raschke M, Walter J, Schirmer H, et al. (2011b). Efficacy and safety of lanthanoids as X-ray contrast agents. Eur J Radiol 80:349–56.
   PubMedGoogle Scholar
• Port M, Idée JM, Medina C, Robic C, Sabatou M, Corot C. (2008). Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals 21:469–90.
   PubMed Web of Science ®Google Scholar
• Posada de la Paz M, Philen RM, Abaitua Borda I. (2001). Toxic oil syndrome: the perspective after 20 years. Epidemiol Rev 23:231–47.
   PubMed Web of Science ®Google Scholar
• Prince MR, Zhang H, Morris M, MacGregor JL, Grossman ME, Silberzweig J, et al. (2008). Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 248:807–16.
   PubMed Web of Science ®Google Scholar
• Rej RN, Holme KR, Perlin AS. (1990). Marked stereoselectivity in the binding of copper ions by heparin. Contrasts with the binding of gadolinium and calcium ions. Carbohydr Res 207:143–52.
   Google Scholar
• Riser BL, Bhagavathula N, Perone P, Garchow K, Xu Y, Fisher GJ, et al. (2012). Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis. J Cell Commun Signal 6:97–105.
   PubMedGoogle Scholar
• Robic C, Catoen S, De Goltstein MC, Idée JM, Port M. (2011). The role of phosphate on Omniscan(®) dechelation: an in vitro relaxivity study at pH 7. Biometals 24:759–68. Erratum in: Biometals 24:769.
   PubMedGoogle Scholar
• Rodby RA. (2011). Can gadolinium be given safely to a patient on dialysis? Semin Dial 24:370–1.
   PubMedGoogle Scholar
• Rofsky NM, Sherry AD, Lenkiski RE. (2008). Nephrogenic systemic fibrosis: a chemical perspective. Radiology 247:608–11.
   PubMed Web of Science ®Google Scholar
• Rowe PSN, Hedge AM, Laurence JS, Lee SP, Brooks WM, McCarthy ET. (2010). Gadodiamide (Gd-OMN) binds circulating ASARM-peptides: a model for nephrogenic systemic fibrosis (NSF). American Society of Nephrology: Renal Week. Denver, CO, USA. J Am Soc Nephrol 21: abstract TH-FC069.
   Google Scholar
• Saab G, Cheng S. (2007). Nephrogenic systemic fibrosis: a nephrologist’s perspective. Hemodial Int 11:S2–S6.
   Google Scholar
• Sachs F. (2010)Stretch-activated ion channels: what are they? Physiology (Bethesda) 25:50–6.
   Google Scholar
• Santhanam AV, D’Uscio LV, Peterson TE, Katusic ZS. (2008). Activation of endothelial nitric oxide synthase is critical for erythropoietin-induced mobilization of progenitor cells. Peptides 29:1451–5.
   PubMedGoogle Scholar
• Sanyal S, Marckmann P, Scherer S, Abraham JL. (2011). Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis—an autopsy-based review. Nephrol Dial Transplant 26:3616–26.
   PubMedGoogle Scholar
• Sato T, Ito K, Tamada T, Kanki A, Watanabe S, Nishimura H, et al. (2013). Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS). Magn Reson Imaging 31:1412–7.
   PubMedGoogle Scholar
• Schieren G, Gambichler T, Skrygan M, Burkert B, Altmeyer P, Rump LC, Kreuter A. (2010). Balance of profibrotic and antifibrotic [corrected] signaling in nephrogenic systemic fibrosis skin lesions. Am J Kidney Dis 55:1040–9.
   PubMed Web of Science ®Google Scholar
• Schmidt-Lauber C, Bossaller L, Abujudeh HH, Vladimer GI, Christ A, Fitzgerald KA, et al. (2014). Gadolinium-based compounds induce NLRP3-dependent IL-1β production and peritoneal inflammation. Ann Rheum Dis (In press).
   PubMedGoogle Scholar
• Schroeder JA, Weingart C, Coras B, Hausser I, Reinhold S, Mack M, et al. (2008). Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 3:968–75.
   PubMedGoogle Scholar
• Shen L, Yang A, Yao P, Sun X, Chen C, Mo C, et al. (2014). Gadolinium promoted proliferation in mouse embryo fibroblast NIH3T3 cells through Rac and PI3K/Akt signaling pathways. Biometals 27:753–62.
   PubMedGoogle Scholar
• Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ. (2008a). A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 43:65–75.
   PubMedGoogle Scholar
• Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, et al. (2008b). Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 18:2164–73.
   PubMed Web of Science ®Google Scholar
• Sieber MA, Lengsfeld P, Walter J, Schirmer H, Frenzel T, Siegmund F, et al. (2008c). Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson Imaging 27:955–62.
   PubMedGoogle Scholar
• Siebert N, Xu W, Grambow E, Zechner D, Vollmar B. (2011). Erythropoietin improves skin wound healing and activates the TGF-β signaling pathway. Lab Invest 91:1753–65.
   PubMedGoogle Scholar
• Smythe WR, Alfrey AC, Craswell PW, Crouch CA, Ibels LS, Kubo H, et al. (1982). Trace element abnormalities in chronic uremia. Ann Intern Med 96:302–10.
   PubMed Web of Science ®Google Scholar
• Soria JC, Blay JY, Spano JP, Pivot X, Coscas Y, Khayat D. (2011). Added value of molecular targeted agents in oncology. Ann Oncol 22:1703–16.
   PubMedGoogle Scholar
• Spencer AJ, Wilson SA, Batchelor J, Reid A, Pees J, Harpur E. (1997). Gadolinium chloride toxicity in the rat. Toxicol Pathol 25:245–55.
   PubMed Web of Science ®Google Scholar
• Steger-Hartmann T, Raschke M, Riefke B, Pietsch H, Sieber MA, Walter J. (2009). The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis – a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp Toxicol Pathol 61:537–52.
   PubMedGoogle Scholar
• Stratta P, Canavese C, Aime S. (2008). Gadolinium-enhanced magnetic resonance imaging, renal failure and nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy. Curr Med Chem 15:1229–35.
   PubMedGoogle Scholar
• Swaminathan S, Ahmed I, McCarthy JT, Albright RC, Pittelkow MR, Caplice NM, et al. (2006). Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 145:234–5.
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Horn TD, Pellowski D, Abul-Ezz S, Bornhorst JA, Viswamitra S, Shah SV. (2007). Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med 357:720–2.
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Shah SV. (2007). New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 18:2636–43.
   PubMed Web of Science ®Google Scholar
• Swaminathan S, High WA, Ranville J, Horn TD, Hiatt K, Thomas M, et al. (2008). Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 73:1413–8.
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Bose C, Shah SV, Hall KA, Hiatt KM. (2013). Gadolinium contrast agent-induced CD163(+) ferroportin(+) osteogenic cells in nephrogenic systemic fibrosis. Am J Pathol 183:796–807.
   PubMedGoogle Scholar
• Taupitz M, Stolzenburg N, Ebert M, Schnorr J, Hauptmann R, Kratz H, et al. (2013). Gadolinium-containing magnetic resonance contrast media: investigation on the possible transchelation of Gd(3+) to the glycosaminoglycan heparin. Contrast Media Mol Imaging 8:108–16.
   PubMedGoogle Scholar
• Thakral C, Abraham JL. (2009). Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in tissues: in vivo transmetallation confirmed by microanalysis. Cutan Pathol 36:1244–54.
   PubMedGoogle Scholar
• Thomsen HS, Bennett CL. (2012). Six years after. Acta Radiol 53: 827–9.
   PubMedGoogle Scholar
• Thomsen HS, Morcos SK, Almén T, Bellin MF, Bertolotto M, Bongartz G, et al. (2013). Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 23:307–18.
   PubMedGoogle Scholar
• Tweedle MF, Wedeking P, Kumar K. (1995). Biodistribution of radiolabeled, formulated gadopentetic acid, gadoteridol, gadoteric acid, and gadodiamide in mice and rats. Invest Radiol 30:372–80.
   PubMed Web of Science ®Google Scholar
• Varani J, DaSilva M, Warner RL, Deming MO, Barron AG, Johnson KJ, Swartz RD. (2009). Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol 44:74–81.
   PubMed Web of Science ®Google Scholar
• Vercruysse KP, Li H, Luo Y, Prestwich GD. (2002). Thermosensitive lanthanide complexes of hyaluronan. Biomacromolecules 3: 639–43.
   PubMedGoogle Scholar
• Vidaud C, Bourgeois D, Meyer D. (2012). Bone as target organ for metals: the case of f-elements. Chem Res Toxicol 25:1161–75.
   PubMed Web of Science ®Google Scholar
• Wadas TJ, Sherman CD, Miner JH, Duncan JR, Anderson CJ. (2010). The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice. Magn Reson Med 64:1274–80.
   PubMedGoogle Scholar
• Wagner B, Tan C, Barnes JL, Ahuja S, Davis TL, Gorin Y, Jimenez F. (2012). Nephrogenic systemic fibrosis: evidence for oxidative stress and bone marrow-derived fibrocytes in skin, liver, and heart lesions using a 5/6 nephrectomy rodent model. Am J Pathol 181:1941–52.
   PubMedGoogle Scholar
• Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, et al. (2011). Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology 260:105–11.
   PubMed Web of Science ®Google Scholar
• Wasserman AJ, Monticello TM, Feldman RS, Gitlitz PH, Durham SK. (1996). Utilization of electron probe microanalysis in gadolinium-treated mice. Toxicol Pathol 24:588–94.
   PubMedGoogle Scholar
• Wedeking P, Kumar K, Tweedle MF,. (1993). Dose-dependent biodistribution of [153Gd]Gd(acetate)n in mice. Nucl Med Biol 20:679–91.
   PubMed Web of Science ®Google Scholar
• Wermuth PJ, Del Galdo F, Jiménez SA. (2009). Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 60:1508–18.
   PubMedGoogle Scholar
• Wermuth PJ, Jiménez SA. (2012a). Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis. J Immunol 189:318–27.
   PubMedGoogle Scholar
• Wermuth PJ, Jiménez SA. (2012b). Intratracheal instillation of Omniscan in an adenine-induced model of chronic renal failure. A new model of nephrogenic systemic fibrosis. Arthr Rheum 64:s974 (abstract).
   Google Scholar
• Wermuth PJ, Jiménez SA. (2014). Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents. Clin Exp Immunol 175:113–25.
   PubMedGoogle Scholar
• White GW, Gibby WA, Tweedle MF. (2006). Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 41:272–8.
   PubMed Web of Science ®Google Scholar
• Wollanka H, Weidenmaier W, Giersig C. (2009). NSF after Gadovist exposure: a case report and hypothesis of NSF development. Nephrol Dial Transplant 24:3882–4.
   PubMedGoogle Scholar
• Wong J. (2012). Gadolinium prescribing trends. The effect of regulatory action. Pharmacoepidemiol Drug Saf (Suppl 3):462–3 (abstract).
   Google Scholar
• Xia D, Davis RL, Crawford JA, Abraham JL. (2010). Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X-ray spectroscopy. Acta Radiol 51:1126–36.
   PubMed Web of Science ®Google Scholar
• Yang L, Krefting I, Gorovets A, Marzella L, Kaiser J, Boucher R, Rieves D. (2012).Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration. Radiology 265:248–53.
   PubMedGoogle Scholar